LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Transcript : Myriad Genetics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM
Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing MT
Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test MT
Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test MT
QIAGEN and Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test for Global Research and Companion Diagnostics Applications CI
Transcript : Myriad Genetics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 05:15 PM
Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating MT
Sector Update: Health Care Stocks Softer Late Afternoon MT
Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue MT
Eurobio Scientific: agreement with Myriad Genetics CF
Eurobio Scientific to Buy Gene Expression Test for Breast Cancer MT
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q1 Revenue $202.2M, vs. Street Est of $193.3M MT
(MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 EPS Range $0.00 - $0.05 MT
(MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 Revenue Range $820M - $840M MT
Myriad Genetics to Seek Acquisitions CI
Transcript : Myriad Genetics, Inc., Q1 2024 Earnings Call, May 07, 2024
Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024 CI
Myriad Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Eurobio Scientific Société anonyme signed a definitive agreement to acquire EndoPredict business of Myriad Genetics, Inc for $10 million. CI
Myriad Genetics Gets US Patent for SneakPeek Snap Device MT
Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q4 EPS $0.04, vs. Street Est of $0.01 MT
(MYGN) MYRIAD GENETICS Forecasts 2024 Revenue Range $820M - $840M MT
Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024 CI
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024 CI
Chart Myriad Genetics, Inc.
More charts
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
24.26 USD
Average target price
25.09 USD
Spread / Average Target
+3.43%
Consensus
  1. Stock Market
  2. Equities
  3. MYGN Stock
  4. News Myriad Genetics, Inc.
  5. (MYGN) MYRIAD GENETICS Sees Fiscal Year 2024 Revenue Range $820M - $840M